ArticleInternational journal of pharmaceutics: X2025

Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease.

Rudy Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.